Publication Delays Impact Careers of Early-Career Researchers

By João L. Carapinha

May 19, 2025

The article “Dear editors, your publication delays are damaging our careers” by Chia-Hsuan Hsu highlights how publication delays hurt careers, especially for early-career researchers. With publication records key for jobs and tenure, slow editorial processes stall academic progress. The author shares waiting 18 months for a decision, blaming poor reviewer recruitment. This calls on editors to improve efficiency.

The Detrimental Impact of Delays

The article notes that publication delays impact careers by harming early-career researchers. Delays can cost job and funding chances, hindering growth. East Asia heavily weighs publication history in evaluations, making delays more damaging than in regions valuing broader contributions. Bottlenecks often stem from poor reviewer recruitment and communication, not scientific merit. While preprints speed up sharing findings, they often don’t count for career evaluations in Japan and Taiwan.

The article reflects broader issues in publishing and evaluation. The global academic system overvalues publications for hiring and funding, pressuring early-career researchers into a publish or perish culture. A few big publishers control the market while unpaid editorial labor leads to slow, profit-driven processes that clash with researchers’ needs. Delays often arise from reviewer shortages and overworked editors, hurting researchers needing timely output.

Proactive Solutions for a Changing Landscape

  • Reforming Academic Evaluation: Reports suggest valuing preprints and datasets more, but until reforms spread, early-career researchers suffer.
  • Innovative Peer Review Models: Open peer review and reviewer incentives could help, needing publisher and institutional cooperation.
  • Policy Recommendations: Health agencies and consortia could recognize preprints in evaluations, easing delays’ harm.

In summary, the article shows how publication delays hurt careers. Fixing this needs changes from editors, publishers, and institutions to ensure fair opportunities. For deeper insights, explore the source material.

Reference url

Recent Posts

NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival

By Staff Writer

August 25, 2025

Bladder cancer treatment has recently advanced, offering new hope for adults with advanced urothelial cancer. If you’re wondering, “What is the most effective first-line bladder cancer treatment for advanced cases in the UK right now?”—the latest update is that the National Institute for Health a...
UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient Access and Market G...
The accelerated review of the UK's Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) concluded without agreement in August 2025. The review focused on soaring payment rates. These require companies to pay up to 35.6% of their revenue from NHS sales. Despite good faith effo...
EFPIA Response to Tariffs: Concerns Over U.S.-EU Trade Agreement Impact on Pharma Industry

By Staff Writer

August 22, 2025

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has expressed significant concern over the new U.S.-EU Joint Framework Agreement. It is particularly worried about potential tariffs of 15% on pharmaceutical products. The organization argues these tariffs break a three...